Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 4 357 JPY -0.37% Market Closed
Market Cap: 338.7B JPY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Hisamitsu Pharmaceutical Co Inc stock under the Base Case scenario is 3 746.87 JPY. Compared to the current market price of 4 357 JPY, Hisamitsu Pharmaceutical Co Inc is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 746.87 JPY
Overvaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2
P/S
P/S
Price to Sales
2
vs History
84
vs Industry
51
Median 3Y
2.2
Median 5Y
2.4
Industry
2.4
Forward
1.9
More Details
14.6
P/E
P/E
Price to Earnings
14.6
vs History
93
vs Industry
25
Median 3Y
22.9
Median 5Y
25
Industry
20.3
Forward
14.1
More Details
16.9
P/OCF
P/OCF
Price to OCF
16.9
vs History
57
vs Industry
27
Median 3Y
17.5
Median 5Y
20.1
Industry
15.6
More Details
48.3
P/FCFE
P/FCFE
Price to FCFE
48.3
vs History
47
vs Industry
0
Median 3Y
58
Median 5Y
48.2
Industry
23.1
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
55
vs Industry
57
Median 3Y
1.1
Median 5Y
1.2
Industry
2
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
63
vs Industry
66
Median 3Y
1.2
Median 5Y
1.4
Industry
2.5
Forward
1.1
More Details
2.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.1
vs History
71
vs Industry
69
Median 3Y
2.1
Median 5Y
2.4
Industry
4.8
More Details
7.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.6
vs History
92
vs Industry
33
Median 3Y
9.7
Median 5Y
10.8
Industry
12.5
Forward
7
More Details
10.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.1
vs History
92
vs Industry
30
Median 3Y
13.9
Median 5Y
14.6
Industry
15.7
More Details
10.2
EV/OCF
EV/OCF
Enterprise Value to OCF
10.2
vs History
60
vs Industry
38
Median 3Y
10.2
Median 5Y
11.1
Industry
14.1
More Details
38.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38.3
vs History
30
vs Industry
0
Median 3Y
33
Median 5Y
29.6
Industry
17.6
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
61
vs Industry
60
Median 3Y
0.9
Median 5Y
1
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Hisamitsu Pharmaceutical Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
317.9B JPY 2 14.6 7.6 10.1
US
Eli Lilly and Co
NYSE:LLY
712.2B USD 14.5 64.1 34.5 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.5B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 18.9 12.5 14.2
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
178.5B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
157.1B GBP 3.8 26.8 130.2 196.3
US
Merck & Co Inc
NYSE:MRK
196.3B USD 3.1 11.3 8.1 9.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.6B USD 2.1 16.6 7.2 10.1
P/E Multiple
Earnings Growth PEG
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average P/E: 23.4
14.6
11%
1.3
US
Eli Lilly and Co
NYSE:LLY
64.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.8
36%
0.7
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.6
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average EV/EBITDA: 394.5
7.6
7%
1.1
US
Eli Lilly and Co
NYSE:LLY
34.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.2
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.1
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Average EV/EBIT: 1 697.9
10.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.7
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.3
21%
9.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.